Skip to content
2000
Volume 22, Issue 2
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Diabetes is a chronic, irreversible, non-infectious metabolic syndrome associated with low insulin production by the pancreas or due to insulin resistance. The management landscape for diabetes is swiftly evolving due to ongoing advancements. Conventional treatment approaches have struggled to fully address the root causes of the disease while also carrying significant risks of adverse effects. Flavonoids are an extensive class of phytonutrients present in grains, vegetables, fruits, cocoa, tea, wine, and nuts. Many studies have reported that flavonoids have shown diversified pharmacological activity in recent years. Thus, this review will give you an overview of the significant anti-diabetic potential of promising flavonoids. Various search engines such as PubMed, Scopus, Google Scholar, and WoS have been explored by using the keywords “apigenin,” “luteolin,” “naringenin,” “hesperidin,” “kaempferol,” “quercetin,” “myricetin” and “taxifolin” with “anti-diabetic.” The anti-diabetic activity of flavonoids is attributed to various mechanisms, including α glucosidase, α-amylase inhibitory effects, GLUT4 expression, antioxidant, and apoptosis. However, their inadequate biopharmaceutical qualities make their effectiveness in clinical translation constrained. This review aims to highlight plant-derived flavonoids through , , and clinical insights. Additionally, the review highlights the recent advancement in the drug delivery system in diabetes to overcome the limitation of flavonoids.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998335480241022084655
2024-11-29
2026-02-24

  • From This Site

    /content/journals/cdr/10.2174/0115733998335480241022084655
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/2/CDR-22-2-01.html?itemId=/content/journals/cdr/10.2174/0115733998335480241022084655&mimeType=html&fmt=ahah

References

  1. OngK.L. StaffordL.K. McLaughlinS.A. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021.Lancet20234021039720323410.1016/S0140‑6736(23)01301‑637356446
     [Google Scholar]
  2. SunH. SaeediP. KarurangaS. PinkepankM. OgurtsovaK. DuncanB.B. SteinC. BasitA. ChanJ.C.N. MbanyaJ.C. PavkovM.E. RamachandaranA. WildS.H. JamesS. HermanW.H. ZhangP. BommerC. KuoS. BoykoE.J. MaglianoD.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res. Clin. Pract.202218310911910.1016/j.diabres.2021.10911934879977
     [Google Scholar]
  3. MathurP. LeburuS. KulothunganV. Prevalence, awareness, treatment and control of diabetes in india from the countrywide national NCD monitoring survey.Front. Public Health20221074815710.3389/fpubh.2022.74815735359772
     [Google Scholar]
  4. BakerC. Is it type 1 or type 2? It may not be so easy.Obesity and Disease in an Interconnected WorldBentham Science PublishersSharjah, UAE Wylie-RosettJ. JhangianiS.S. 201510211310.2174/9781681080369115010011
     [Google Scholar]
  5. HossainM.J. Al-MamunM. IslamM.R. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused.Health Sci. Rep.202473e200410.1002/hsr2.2004
     [Google Scholar]
  6. SoleK.B. StaffA.C. LaineK. Maternal diseases and risk of hypertensive disorders of pregnancy across gestational age groups.Pregnancy Hypertens.202125253310.1016/j.preghy.2021.05.00434022624
     [Google Scholar]
  7. ShamsadA. KushwahA.S. SinghR. BanerjeeM. Pharmaco-epi-genetic and patho-physiology of gestational diabetes mellitus (GDM): An overview.Health Sci. Rev. (Oxf.)2023710008610.1016/j.hsr.2023.100086
     [Google Scholar]
  8. TwaijB.M. HasanM.N. Bioactive secondary metabolites from plant sources: Types, synthesis, and their therapeutic uses.Int. J. Plant Biol.202213141410.3390/ijpb13010003
     [Google Scholar]
  9. RiazA. RasulA. KanwalN. HussainG. ShahM.A. SarfrazI. IshfaqR. BatoolR. RukhsarF. AdemŞ. Germacrone: A potent secondary metabolite with therapeutic potential in metabolic diseases, cancer and viral infections.Curr. Drug Metab.202021141079109010.2174/138920022199920072814480132723267
     [Google Scholar]
  10. MahajanM. KuiryR. PalP.K. Understanding the consequence of environmental stress for accumulation of secondary metabolites in medicinal and aromatic plants.J. Appl. Res. Med. Aromat. Plants20201810025510.1016/j.jarmap.2020.100255
     [Google Scholar]
  11. LiL.Z. YanY. SongQ. WangZ. ZhangW. HouY. ZhangX. Impacts of plant-derived secondary metabolites for improving flora in type 2 diabetes.Curr. Diabetes Rev.2023197e16012321275010.2174/157339981966623011611185636650624
     [Google Scholar]
  12. SoltaniD. AziziB. RahimiR. TalasazA.H. RezaeizadehH. Vasheghani-FarahaniA. Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: A comprehensive review of preclinical and clinical evidence.Front. Cardiovasc. Med.2022999006310.3389/fcvm.2022.99006336247473
     [Google Scholar]
  13. VermaT. SinhaM. BansalN. YadavS.R. ShahK. ChauhanN.S. Plants used as antihypertensive.Nat. Prod. Bioprospect.202111215518410.1007/s13659‑020‑00281‑x33174095
     [Google Scholar]
  14. PrayogaD. AulifaD. BudimanA. LevitaJ. Plants with anti-ulcer activity and mechanism: A review of preclinical and clinical studies.Drug Des. Devel. Ther.20241819321310.2147/DDDT.S44694938318501
     [Google Scholar]
  15. BekonoB.D. Ntie-KangF. OnguénéP.A. LifongoL.L. SipplW. FesterK. OwonoL.C.O. The potential of anti-malarial compounds derived from African medicinal plants: A review of pharmacological evaluations from 2013 to 2019.Malar. J.202019118310.1186/s12936‑020‑03231‑732423415
     [Google Scholar]
  16. FakhriS. MoradiS.Z. Ash-RafzadehA. BishayeeA. Targeting cellular senescence in cancer by plant secondary metabolites: A systematic review.Pharmacol. Res.202217710596110.1016/j.phrs.2021.10596134718135
     [Google Scholar]
  17. YuandaniJ.I. JantanI. SalimE. SeptamaA.W. RullahK. NainuF. Fasihi Mohd AluwiM.F. EmranT.B. RoneyM. KhairunnisaN.A. NasutionH.R. Fadhil As’adM. ShamsudinN.F. AbdullahM.A. Marwa RaniH.L. Al ChairaD.M. AuliaN. Mechanistic insights into anti-inflammatory and immunosuppressive effects of plant secondary metabolites and their therapeutic potential for rheumatoid arthritis.Phytother. Res.20243862931296110.1002/ptr.814738600726
     [Google Scholar]
  18. GhoshS. SarkarT. ChakrabortyR. Ankol plant (Alangium salvifolium) - The treasure trove of bioactives and medicinal potential.Food Biosci.20235110223010.1016/j.fbio.2022.102230
     [Google Scholar]
  19. ChamkhiI. BenaliT. AannizT. El MenyiyN. GuaouguaouF.E. El OmariN. El-ShazlyM. ZenginG. BouyahyaA. Plant-microbial interaction: The mechanism and the application of microbial elicitor induced secondary metabolites biosynthesis in medicinal plants.Plant Physiol. Biochem.202116726929510.1016/j.plaphy.2021.08.00134391201
     [Google Scholar]
  20. PattanaikS.K. AnilP.M. PatyarS. Underlying mechanisms of Astragalus membranaceus in the treatment of multiple-sclerosis.RE:view2023280002018810.1063/5.0163351
     [Google Scholar]
  21. ChenB. ZhaoJ. ZhangR. ZhangL. ZhangQ. YangH. AnJ. Neuroprotective effects of natural compounds on neurotoxin-induced oxidative stress and cell apoptosis.Nutr. Neurosci.20222551078109910.1080/1028415X.2020.184003533164705
     [Google Scholar]
  22. TeohE.S. Secondary metabolites of plants.Medicinal Orchids of AsiaChamSpringer2016597310.1007/978‑3‑319‑24274‑3_5
     [Google Scholar]
  23. AdhikaryS. DasguptaN. Role of secondary metabolites in plant homeostasis during biotic stress.Biocatal. Agric. Biotechnol.20235010271210.1016/j.bcab.2023.102712
     [Google Scholar]
  24. EkaluA. HabilaJ.D. Flavonoids: Isolation, characterization, and health benefits.Beni. Suef Univ. J. Basic Appl. Sci.2020914510.1186/s43088‑020‑00065‑9
     [Google Scholar]
  25. AL-IshaqR.K. AbotalebM. KubatkaP. KajoK. BüsselbergD. Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels.Biomolecules20199943010.3390/biom909043031480505
     [Google Scholar]
  26. OliveiraA.K.S. de Oliveira e SilvaA.M. PereiraR.O. SantosA.S. Barbosa JuniorE.V. BezerraM.T. BarretoR.S.S. Quintans-JuniorL.J. QuintansJ.S.S. Anti-obesity properties and mechanism of action of flavonoids: A review.Crit. Rev. Food Sci. Nutr.202262287827784810.1080/10408398.2021.191905133970708
     [Google Scholar]
  27. ZhangJ. Mao-mao ShaoM. WangM. Therapeutic potential of natural flavonoids in pulmonary arterial hypertension: A review.Phytomedicine202412815553510.1016/j.phymed.2024.15553538537442
     [Google Scholar]
  28. MirS.A. DarA. HamidL. NisarN. MalikJ.A. AliT. BaderG.N. Flavonoids as promising molecules in the cancer therapy: An insight.Curr. Res. Pharmacol. Drug Discov.2024610016710.1016/j.crphar.2023.10016738144883
     [Google Scholar]
  29. LvD. ChengX. TangL. JiangM. The cardioprotective effect of total flavonoids on myocardial ischemia/reperfusion in rats.Biomed. Pharmacother.20178827728410.1016/j.biopha.2017.01.06028110194
     [Google Scholar]
  30. EbrahimiF. GhazimoradiM.M. FatimaG. BahramsoltaniR. Citrus flavonoids and adhesion molecules: Potential role in the management of atherosclerosis.Heliyon2023911e2184910.1016/j.heliyon.2023.e2184938028000
     [Google Scholar]
  31. WuR. ZhuX. GuanG. CuiQ. ZhuL. XingY. ZhaoJ. Association of dietary flavonoid intakes with prevalence of chronic respiratory diseases in adults.J. Transl. Med.202422120510.1186/s12967‑024‑04949‑738409037
     [Google Scholar]
  32. PatelS. MathanJ.J. VaghefiE. BraakhuisA.J. The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: A systematic review and meta-analysis.Graefes Arch. Clin. Exp. Ophthalmol.2015253111841185010.1007/s00417‑015‑3168‑y26340868
     [Google Scholar]
  33. LiuF. BaiY. WanY. HeJ. LiQ. XieY. GuoP. Mechanism of flavonoids in the treatment of gouty arthritis (Review).Mol. Med. Rep.202430213210.3892/mmr.2024.1325638818832
     [Google Scholar]
  34. ChoyK.W. MuruganD. LeongX.F. AbasR. AliasA. MustafaM.R. Flavonoids as natural anti-inflammatory agents targeting nuclear factor-kappa B (NFκB) signaling in cardiovascular diseases: A mini review.Front. Pharmacol.201910129510.3389/fphar.2019.0129531749703
     [Google Scholar]
  35. ChenS. WangX. ChengY. GaoH. ChenX. A review of classification, biosynthesis, biological activities and potential applications of flavonoids.Molecules20232813498210.3390/molecules2813498237446644
     [Google Scholar]
  36. BabuP.V.A. LiuD. GilbertE.R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids.J. Nutr. Biochem.201324111777178910.1016/j.jnutbio.2013.06.00324029069
     [Google Scholar]
  37. ProençaC. RibeiroD. FreitasM. FernandesE. Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α-amylase and α-glucosidase activity: A review.Crit. Rev. Food Sci. Nutr.202262123137320710.1080/10408398.2020.186275533427491
     [Google Scholar]
  38. XiaoJ. Dietary flavonoid aglycones and their glycosides: Which show better biological significance?Crit. Rev. Food Sci. Nutr.57918741905201510.1080/10408398.2015.1032400
     [Google Scholar]
  39. FuZ. GilbertE.R. LiuD. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes.Curr. Diabetes Rev.201391255310.2174/15733991380414322522974359
     [Google Scholar]
  40. RahmanM.S. HossainK.S. DasS. KunduS. AdegokeE.O. RahmanM.A. HannanM.A. UddinM.J. PangM.G. Role of insulin in health and disease: An update.Int. J. Mol. Sci.20212212640310.3390/ijms2212640334203830
     [Google Scholar]
  41. RuiL. Energy metabolism in the liver.Compr. Physiol.20144117719710.1002/cphy.c13002424692138
     [Google Scholar]
  42. WhitticarN.B. NunemakerC.S. Reducing glucokinase activity to enhance insulin secretion: A counterintuitive theory to preserve cellular function and glucose homeostasis.Front. Endocrinol. (Lausanne)20201137810.3389/fendo.2020.0037832582035
     [Google Scholar]
  43. AntarS.A. AshourN.A. SharakyM. KhattabM. AshourN.A. ZaidR.T. RohE.J. ElkamhawyA. Al-KarmalawyA.A. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments.Biomed. Pharmacother.202316811573410.1016/j.biopha.2023.11573437857245
     [Google Scholar]
  44. VelikovaT.V. KabakchievaP.P. AssyovY.S. GeorgievT.А. Targeting inflammatory cytokines to improve type 2 diabetes control.BioMed Res. Int.2021202111210.1155/2021/729741934557550
     [Google Scholar]
  45. PollackR.M. DonathM.Y. LeRoithD. LeibowitzG. Anti-inflammatory agents in the treatment of diabetes and its vascular complications.Diabetes Care201639 Suppl. 2S244S25210.2337/dcS15‑301527440839
     [Google Scholar]
  46. TsalamandrisS. AntonopoulosA.S. OikonomouE. PapamikroulisG.A. VogiatziG. PapaioannouS. DeftereosS. TousoulisD. The role of inflammation in diabetes: Current concepts and future perspectives.Eur. Cardiol.2019141505910.15420/ecr.2018.33.131131037
     [Google Scholar]
  47. NedosugovaL.V. MarkinaY.V. BochkarevaL.A. KuzinaI.A. PetuninaN.A. YudinaI.Y. KirichenkoT.V. Inflammatory mechanisms of diabetes and its vascular complications.Biomedicines2022105116810.3390/biomedicines1005116835625904
     [Google Scholar]
  48. van SlounB. GoossensG. ErdosB. LenzM. van RielN. ArtsI. The impact of amino acids on postprandial glucose and insulin kinetics in humans: A quantitative overview.Nutrients20201210321110.3390/nu1210321133096658
     [Google Scholar]
  49. TanaseD.M. GosavE.M. BotocT. FloriaM. TarniceriuC.C. MaranducaM.A. HaisanA. CucuA.I. RezusC. CosteaC.F. Depiction of Branched-Chain Amino Acids (BCAAs) in diabetes with a focus on diabetic microvascular complications.J. Clin. Med.20231218605310.3390/jcm1218605337762992
     [Google Scholar]
  50. ZakariaN.F. HamidM. KhayatM.E. Amino acid-induced impairment of insulin signaling and involvement of G-protein coupling receptor.Nutrients2021137222910.3390/nu1307222934209599
     [Google Scholar]
  51. KoziełK. UrbanskaE.M. Kynurenine pathway in diabetes mellitus - Novel pharmacological target?Cells202312346010.3390/cells1203046036766803
     [Google Scholar]
  52. DingY. WangS. LuJ. Unlocking the potential: Amino acids’ role in predicting and exploring therapeutic avenues for type 2 diabetes mellitus.Metabolites2023139101710.3390/metabo1309101737755297
     [Google Scholar]
  53. OlaM.S. Reduced tyrosine and serine-632 phosphorylation of insulin receptor substrate-1 in the gastrocnemius muscle of obese zucker rat.Curr. Issues Mol. Biol.202244126015602710.3390/cimb4412041036547071
     [Google Scholar]
  54. LuoH.H. FengX.F. YangX.L. HouR.Q. FangZ.Z. Interactive effects of asparagine and aspartate homeostasis with sex and age for the risk of type 2 diabetes risk.Biol. Sex Differ.20201115810.1186/s13293‑020‑00328‑133092635
     [Google Scholar]
  55. HolmL.J. BuschardK. L-serine: A neglected amino acid with a potential therapeutic role in diabetes.Acta Pathol. Microbiol. Scand. Suppl.20191271065565910.1111/apm.1298731344283
     [Google Scholar]
  56. ChenY. MichalakM. AgellonL.B. Importance of nutrients and nutrient metabolism on human health.Yale J. Biol. Med.20189129510329955217
     [Google Scholar]
  57. ShettyS. KumariS. Fatty acids and their role in type-2 diabetes (review).Exp. Ther. Med.202122170610.3892/etm.2021.1013834007315
     [Google Scholar]
  58. DobrianA.D. LiebD.C. ColeB.K. Taylor-FishwickD.A. ChakrabartiS.K. NadlerJ.L. Functional and pathological roles of the 12- and 15-lipoxygenases.Prog. Lipid Res.201150111513110.1016/j.plipres.2010.10.00520970452
     [Google Scholar]
  59. MilsteinJ.L. FerrisH.A. The brain as an insulin-sensitive metabolic organ.Mol. Metab.20215210123410.1016/j.molmet.2021.10123433845179
     [Google Scholar]
  60. MagnanC. LevinB.E. LuquetS. Brain lipid sensing and the neural control of energy balance.Mol. Cell. Endocrinol.2015418Pt 13810.1016/j.mce.2015.09.01926415589
     [Google Scholar]
  61. KomarnytskyS. RathinasabapathyT. WagnerC. MetzgerB. CarlisleC. PandaC. Le Brun-BlashkaS. TroupJ.P. VaradharajS. Endocannabinoid system and its regulation by polyunsaturated fatty acids and full spectrum hemp oils.Int. J. Mol. Sci.20212211547910.3390/ijms2211547934067450
     [Google Scholar]
  62. SiesH. JonesD.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents.Nat. Rev. Mol. Cell Biol.202021736338310.1038/s41580‑020‑0230‑332231263
     [Google Scholar]
  63. GiaccoF. BrownleeM. Oxidative stress and diabetic complications.Circ. Res.201010791058107010.1161/CIRCRESAHA.110.22354521030723
     [Google Scholar]
  64. SinghA. KukretiR. SasoL. KukretiS. Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes.Molecules202227395010.3390/molecules2703095035164215
     [Google Scholar]
  65. BoucherJ. KleinriddersA. KahnC.R. Insulin receptor signaling in normal and insulin-resistant states.Cold Spring Harb. Perspect. Biol.201461a009191a00919110.1101/cshperspect.a00919124384568
     [Google Scholar]
  66. WangT. WangJ. HuX. HuangX. ChenG.X. Current understanding of glucose transporter 4 expression and functional mechanisms.World J. Biol. Chem.2020113769810.4331/wjbc.v11.i3.7633274014
     [Google Scholar]
  67. MiaoL. ZhangH. CheongM.S. ZhongR. Garcia-OliveiraP. PrietoM.A. ChengK-W. WangM. CaoH. NieS. Simal-GandaraJ. CheangW.S. XiaoJ. Anti-diabetic potential of apigenin, luteolin, and baicalein via partially activating PI3K/Akt/Glut-4 signaling pathways in insulin-resistant HepG2 cells.Food Sci. Hum. Wellness20231261991200010.1016/j.fshw.2023.03.021
     [Google Scholar]
  68. IhimS.A. KanekoY.K. YamamotoM. YamaguchiM. KimuraT. IshikawaT. Apigenin alleviates endoplasmic reticulum stress-mediated apoptosis in INS-1 β-cells.Biol. Pharm. Bull.202346463063510.1248/bpb.b22‑0091337005308
     [Google Scholar]
  69. KhallafI.S.A. WahmanR. FarghalyH.S.M. BayoumiS.A.L. The inhibitory effect of doum palm (Hyphaene thebaica L. Mart.) leaves extract on α-glucosidase activity.Bull. Pharm. Sci. Assiut Univ.202245116317610.21608/bfsa.2022.239375
     [Google Scholar]
  70. LiuH. HuangP. WangX. MaY. TongJ. LiJ. DingH. Apigenin analogs as α-glucosidase inhibitors with antidiabetic activity.Bioorg. Chem.202414310705910.1016/j.bioorg.2023.10705938154388
     [Google Scholar]
  71. MiaoL. CheongM.S. ZhouC. FaragM. CheangW.S. XiaoJ. Apigenin alleviates diabetic endothelial dysfunction through activating AMPK/PI3K/Akt/eNOS and Nrf2/HO-1 signaling pathways.Food Front.20234142043110.1002/fft2.192
     [Google Scholar]
  72. HossainC.M. GhoshM.K. SatapathyB.S. DeyN.S. MukherjeeB. Apigenin causes biochemical modulation, GLUT4 and CD38 alterations to improve diabetes and to protect damages of some vital organs in experimental diabetes.Am. J. Pharmacol. Toxicol.201491395210.3844/ajptsp.2014.39.52
     [Google Scholar]
  73. LiP. BukhariS.N.A. KhanT. ChittiR. BevoorD.B. HiremathA.R. SreeHarshaN. SinghY. GubbiyappaK.S. Apigenin-loaded solid lipid nanoparticle attenuates diabetic nephropathy induced by streptozotocin nicotinamide through Nrf2/HO-1/NF-kB signalling pathway.Int. J. Nanomedicine2020159115912410.2147/IJN.S25649433244230
     [Google Scholar]
  74. Gamal SherifS. TarekM. Gamal SabryY. Hassan Abou GhaliaA. Effect of apigenin on dynamin-related protein 1 in type 1 diabetic rats with cardiovascular complications.Gene202489814810710.1016/j.gene.2023.14810738141690
     [Google Scholar]
  75. HanM. LuY. TaoY. ZhangX. DaiC. ZhangB. XuH. LiJ. Luteolin protects pancreatic β cells against apoptosis through regulation of autophagy and ROS clearance.Pharmaceuticals (Basel)202316797510.3390/ph1607097537513887
     [Google Scholar]
  76. ZangY. IgarashiK. LiY. Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A(y) mice.Biosci. Biotechnol. Biochem.20168081580158610.1080/09168451.2015.111692827170065
     [Google Scholar]
  77. WangG.G. LuX.H. LiW. ZhaoX. ZhangC. Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats.Evid. Based Complement. Alternat. Med.20112011132317110.1155/2011/32317121584231
     [Google Scholar]
  78. DaudeR.B. BhadaneR. ShahJ.S. Luteolin attenuates diabetic nephropathy via inhibition of metalloenzymes in rats.Asian Pac. J. Trop. Biomed.2023131250752010.4103/2221‑1691.391156
     [Google Scholar]
  79. AhmedE.S.A. MohamedH.E. FarragM.A. Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway.Int. J. Immunopathol. Pharmacol.2022360394632022113743510.1177/0394632022113743536319192
     [Google Scholar]
  80. GeX. HeX. LiuJ. ZengF. ChenL. XuW. ShaoR. HuangY. FaragM.A. CapanogluE. El-SeediH.R. ZhaoC. LiuB. Amelioration of type 2 diabetes by the novel 6, 8-guanidyl luteolin quinone-chromium coordination via biochemical mechanisms and gut microbiota interaction.J. Adv. Res.20234617318810.1016/j.jare.2022.06.00335700921
     [Google Scholar]
  81. ZhangM. HeL. LiuJ. ZhouL. Luteolin attenuates diabetic nephropathy through suppressing inflammatory response and oxidative stress by inhibiting STAT3 pathway.Exp. Clin. Endocrinol. Diabetes20211291072973910.1055/a‑0998‑798531896157
     [Google Scholar]
  82. KahkshaA.O. AlamO. Al-KeridisL.A. KhanJ. NaazS. AlamA. AshrafS.A. AlshammariN. AdnanM. BegM.A. Evaluation of antidiabetic effect of luteolin in stz induced diabetic rats: Molecular docking, molecular dynamics, in vitro and in vivo studies.J. Funct. Biomater.202314312610.3390/jfb1403012636976050
     [Google Scholar]
  83. LiS. ZhangY. SunY. ZhangG. BaiJ. GuoJ. SuX. DuH. CaoX. YangJ. WangT. Naringenin improves insulin sensitivity in gestational diabetes mellitus mice through AMPK.Nutr. Diabetes2019912810.1038/s41387‑019‑0095‑831591391
     [Google Scholar]
  84. SinghP. BansalS. KuhadA. KumarA. ChopraK. Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels.Food Funct.20201154548456010.1039/C9FO00881K32400767
     [Google Scholar]
  85. Nguyen-NgoC. WillcoxJ.C. LappasM. Anti-diabetic, anti-inflammatory, and anti-oxidant effects of naringenin in an in vitro human model and an in vivo murine model of gestational diabetes mellitus.Mol. Nutr. Food Res.20196319190022410.1002/mnfr.20190022431343820
     [Google Scholar]
  86. DayarathneL.A. RanaweeraS.S. NatrajP. RajanP. LeeY.J. HanC.H. The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells.J. Vet. Sci.2021226e9210.4142/jvs.2021.22.e9234854271
     [Google Scholar]
  87. ZaidunN.H. SahemaZ.C.T. MardianaA.A. SanthanaR.L. LatiffA.A. Syed Ahmad FuadS.B. Effects of naringenin on vascular changes in prolonged hyperglycaemia in fructose-STZ diabetic rat model.Drug Discov. Ther.201913421222110.5582/ddt.2019.0103431534073
     [Google Scholar]
  88. RajappaR. SireeshD. SalaiM.B. RamkumarK.M. SarvajayakesavuluS. MadhunapantulaS.V. Treatment with naringenin elevates the activity of transcription factor Nrf2 to protect pancreatic β-cells from streptozotocin-induced diabetes in vitro and in vivo.Front. Pharmacol.20199156210.3389/fphar.2018.0156230745874
     [Google Scholar]
  89. PriscillaD.H. RoyD. SureshA. KumarV. ThirumuruganK. Naringenin inhibits α-glucosidase activity: A promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats.Chem. Biol. Interact.2014210778510.1016/j.cbi.2013.12.01424412302
     [Google Scholar]
  90. PriscillaD.H. JayakumarM. ThirumuruganK. Flavanone naringenin: An effective antihyperglycemic and antihyperlipidemic nutraceutical agent on high fat diet fed streptozotocin induced type 2 diabetic rats.J. Funct. Foods20151436337310.1016/j.jff.2015.02.005
     [Google Scholar]
  91. RehmanK. KhanI.I. AkashM.S.H. JabeenK. HaiderK. Naringenin downregulates inflammation-mediated nitric oxide overproduction and potentiates endogenous antioxidant status during hyperglycemia.J. Food Biochem.20204410e1342210.1111/jfbc.1342232770581
     [Google Scholar]
  92. MaityS. MukhopadhyayP. KunduP.P. ChakrabortiA.S. Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals - An in vitro and in vivo approach.Carbohydr. Polym.201717012413210.1016/j.carbpol.2017.04.06628521977
     [Google Scholar]
  93. JayaramanR. SubramaniS. Sheik AbdullahS.H. UdaiyarM. Antihyperglycemic effect of hesperetin, a citrus flavonoid, extenuates hyperglycemia and exploring the potential role in antioxidant and antihyperlipidemic in streptozotocin-induced diabetic rats.Biomed. Pharmacother.2018979810610.1016/j.biopha.2017.10.10229080465
     [Google Scholar]
  94. YoshidaH. TsuhakoR. SugitaC. KurokawaM. Glucosyl hesperidin has an anti-diabetic effect in high-fat diet-induced obese mice.Biol. Pharm. Bull.202144342243010.1248/bpb.b20‑0084933642550
     [Google Scholar]
  95. LeeA. GuH. GwonM.H. YunJ.M. Hesperetin suppresses LPS/high glucose-induced inflammatory responses via TLR/MyD88/NF-κB signaling pathways in THP-1 cells.Nutr. Res. Pract.202115559160310.4162/nrp.2021.15.5.59134603607
     [Google Scholar]
  96. JiX. ZhangC. YangJ. TianY. YouL. YangH. LiY. LiuH. PanD. LiuZ. Kaempferol improves exercise performance by regulating glucose uptake, mitochondrial biogenesis, and protein synthesis via PI3K/AKT and MAPK signaling pathways.Foods2024137106810.3390/foods1307106838611372
     [Google Scholar]
  97. KitakazeT. JiangH. NomuraT. HironaoK. YamashitaY. AshidaH. Kaempferol promotes glucose uptake in myotubes through a JAK2-dependent pathway.J. Agric. Food Chem.20206847137201372910.1021/acs.jafc.0c0523633197173
     [Google Scholar]
  98. ZhangY. LiuD. Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function.Eur. J. Pharmacol.2011670132533210.1016/j.ejphar.2011.08.01121914439
     [Google Scholar]
  99. KashyapB. SaikiaK. SamantaS.K. ThakurD. BanerjeeS.K. BorahJ.C. TalukdarN.C. Kaempferol 3-O-rutinoside from Antidesma acidum Retz. Stimulates glucose uptake through SIRT1 induction followed by GLUT4 translocation in skeletal muscle L6 cells.J. Ethnopharmacol.202330111578810.1016/j.jep.2022.11578836223844
     [Google Scholar]
  100. AlkhalidyH. MooreW. WangY. LuoJ. McMillanR.P. ZhenW. ZhouK. LiuD. The flavonoid kaempferol ameliorates streptozotocin-induced diabetes by suppressing hepatic glucose production.Molecules2018239233810.3390/molecules2309233830216981
     [Google Scholar]
  101. DhanyaR. AryaA.D. NishaP. JayamurthyP. Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line.Front. Pharmacol.2017833610.3389/fphar.2017.0033628642704
     [Google Scholar]
  102. OyedemiS.O. NwaoguG. ChukwumaC.I. AdeyemiO.T. MatsabisaM.G. SwainS.S. AiyegoroO.A. Quercetin modulates hyperglycemia by improving the pancreatic antioxidant status and enzymes activities linked with glucose metabolism in type 2 diabetes model of rats: In silico studies of molecular interaction of quercetin with hexokinase and catalase.J. Food Biochem.2020442e1312710.1111/jfbc.1312731876980
     [Google Scholar]
  103. YarahmadiA. KhademiF. Mostafavi-PourZ. ZalF. In-vitro analysis of glucose and quercetin effects on m-TOR and Nrf-2 expression in HepG2 cell line (diabetes and cancer connection).Nutr. Cancer201870577077510.1080/01635581.2018.147065429781726
     [Google Scholar]
  104. JeongS.M. KangM.J. ChoiH.N. KimJ.H. KimJ.I. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice.Nutr. Res. Pract.20126320120710.4162/nrp.2012.6.3.20122808343
     [Google Scholar]
  105. DongB. ShiZ. DongY. ChenJ. WuZ.X. WuW. ChenZ.S. HanC. Quercetin ameliorates oxidative stress-induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats.Biomed. Pharmacother.202215111310810.1016/j.biopha.2022.11310835594707
     [Google Scholar]
  106. AlamM.M. MeerzaD. NaseemI. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice.Life Sci.2014109181410.1016/j.lfs.2014.06.00524946265
     [Google Scholar]
  107. JiangH. HoriuchiY. HironaoK. KitakazeT. YamashitaY. AshidaH. Prevention effect of quercetin and its glycosides on obesity and hyperglycemia through activating AMPKα in high-fat diet-fed ICR mice.J. Clin. Biochem. Nutr.2020671758310.3164/jcbn.20‑4732801472
     [Google Scholar]
  108. ZhangY. DongH. WangM. ZhangJ. Quercetin isolated from Toona sinensis leaves attenuates hyperglycemia and protects hepatocytes in high-carbohydrate/high-fat diet and alloxan induced experimental diabetic mice.J. Diabetes Res.2016201611010.1155/2016/849278027975068
     [Google Scholar]
  109. KimJ.H. KangM.J. ChoiH.N. JeongS.M. LeeY.M. KimJ.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus.Nutr. Res. Pract.20115210711110.4162/nrp.2011.5.2.10721556223
     [Google Scholar]
  110. GaballahH.H. ZakariaS.S. MwafyS.E. TahoonN.M. EbeidA.M. Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats.Biomed. Pharmacother.20179233133910.1016/j.biopha.2017.05.08628554128
     [Google Scholar]
  111. PengJ. LiQ. LiK. ZhuL. LinX. LinX. ShenQ. LiG. XieX. Quercetin improves glucose and lipid metabolism of diabetic rats: Involvement of Akt signaling and SIRT1.J. Diabetes Res.2017201711010.1155/2017/341730629379801
     [Google Scholar]
  112. ZhangF. FengJ. ZhangJ. KangX. QianD. Quercetin modulates AMPK/SIRT1/NF-κB signaling to inhibit inflammatory/oxidative stress responses in diabetic high fat diet-induced atherosclerosis in the rat carotid artery.Exp. Ther. Med.2020206110.3892/etm.2020.941033200005
     [Google Scholar]
  113. YangD.K. KangH.S. Anti-diabetic effect of cotreatment with quercetin and resveratrol in streptozotocin-induced diabetic rats.Biomol. Ther. (Seoul)201826213013810.4062/biomolther.2017.25429462848
     [Google Scholar]
  114. LiY. ZhengX. YiX. LiuC. KongD. ZhangJ. GongM. Myricetin: A potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.FASEB J.20173162603261110.1096/fj.201601339R28270518
     [Google Scholar]
  115. ZhaoZ. ChenY. LiX. ZhuL. WangX. LiL. SunH. HanX. LiJ. Myricetin relieves the symptoms of type 2 diabetes mice and regulates intestinal microflora.Biomed. Pharmacother.202215311353010.1016/j.biopha.2022.11353036076610
     [Google Scholar]
  116. KarunakaranU. ElumalaiS. MoonJ.S. JeonJ.H. KimN.D. ParkK.G. WonK.C. LeemJ. LeeI.K. Myricetin protects against high glucose-induced β-cell apoptosis by attenuating endoplasmic reticulum stress via inactivation of cyclin-dependent kinase 5.Diabetes Metab. J.201943219220510.4093/dmj.2018.005230688049
     [Google Scholar]
  117. YangL. GaoY. GongJ. WangH. FaragM.A. Simal-GandaraJ. ZhaoY. NieS. XiaoJ. Myricetin ameliorated prediabetes via immunomodulation and gut microbiota interaction.Food Front.20223474977210.1002/fft2.152
     [Google Scholar]
  118. KangS.J. ParkJ.H.Y. ChoiH.N. KimJ.I. α-glucosidase inhibitory activities of myricetin in animal models of diabetes mellitus.Food Sci. Biotechnol.20152451897190010.1007/s10068‑015‑0249‑y
     [Google Scholar]
  119. NallappanD. OngK.C. PalanisamyU.D. ChuaK.H. KuppusamyU.R. Myricetin derivative-rich fraction from Syzygium malaccense prevents high-fat diet-induced obesity, glucose intolerance and oxidative stress in C57BL/6J mice.Arch. Physiol. Biochem.2023129118619710.1080/13813455.2020.180801932813560
     [Google Scholar]
  120. LiY.X. ChengK.C. LiuI.M. NiuH.S. Myricetin increases circulating adropin level after activation of Glucagon-like Peptide 1 (GLP-1) receptor in type-1 diabetic rats.Pharmaceuticals (Basel)202215217310.3390/ph1502017335215286
     [Google Scholar]
  121. LalithaN. SadashivaiahB. RamaprasadT.R. SinghS.A. Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein.PLoS One2020154e023154310.1371/journal.pone.023154332282828
     [Google Scholar]
  122. AhiskaliI. PinarC.L. KikiM. MammadovR. Ozbek BilginA. HacimuftuogluA. CankayaM. Keskin CimenF. AltunerD. Effect of taxifolin on development of retinopathy in alloxan-induced diabetic rats.Cutan. Ocul. Toxicol.201938322723210.1080/15569527.2019.158828930897968
     [Google Scholar]
  123. GurumayumS. BharadwajS. SheikhY. BargeS.R. SaikiaK. SwargiaryD. AhmedS.A. ThakurD. BorahJ.C. Taxifolin-3-O-glucoside from Osbeckia nepalensis Hook. mediates antihyperglycemic activity in CC1 hepatocytes and in diabetic Wistar rats via regulating AMPK/G6Pase/PEPCK signaling axis.J. Ethnopharmacol.202330311593610.1016/j.jep.2022.11593636403743
     [Google Scholar]
  124. TaldaevA. SavinaA.D. OlichevaV.V. IvanovS.V. TerekhovR.P. IlyasovI.R. ZhevlakovaA.K. SelivanovaI.A. Protective properties of spheroidal taxifolin form in streptozotocin-induced diabetic rats.Int. J. Mol. Sci.202324151196210.3390/ijms24151196237569337
     [Google Scholar]
  125. KondoS. AdachiS. YoshizawaF. YagasakiK. Antidiabetic effect of taxifolin in cultured l6 myotubes and type 2 diabetic model kk-ay/ta mice with hyperglycemia and hyperuricemia.Curr. Issues Mol. Biol.20214331293130610.3390/cimb4303009234698101
     [Google Scholar]
  126. RehmanK. ChohanT.A. WaheedI. GilaniZ. AkashM.S.H. Taxifolin prevents postprandial hyperglycemia by regulating the activity of α-amylase: Evidence from an in vivo and in silico studies.J. Cell. Biochem.2019120142543810.1002/jcb.2739830191607
     [Google Scholar]
  127. LengyelM. Kállai-SzabóN. AntalV. LakiA.J. AntalI. Microparticles, microspheres, and microcapsules for advanced drug delivery.Sci. Pharm.20198732010.3390/scipharm87030020
     [Google Scholar]
  128. Kállai-SzabóN. FarkasD. LengyelM. BasaB. FleckC. AntalI. Microparticles and multi-unit systems for advanced drug delivery.Eur. J. Pharm. Sci.202419410670410.1016/j.ejps.2024.10670438228279
     [Google Scholar]
  129. ShuklaS. PanditV. Trojan microparticles : A composite nanoparticle delivery system.Curr. Drug Ther.202419441342510.2174/1574885518666230726142855
     [Google Scholar]
  130. BaleS. KhuranaA. ReddyA.S.S. SinghM. GoduguC. Overview on therapeutic applications of microparticulate drug delivery systems.Crit. Rev. Ther. Drug Carrier Syst.201633430936110.1615/CritRevTherDrugCarrierSyst.201601579827910739
     [Google Scholar]
  131. RafieeM.H. Abdul RasoolB.K. An overview of microparticulate drug delivery system and its extensive therapeutic applications in diabetes.Adv. Pharm. Bull.202112473074610.34172/apb.2022.07536415632
     [Google Scholar]
  132. SafariJ. ZarnegarZ. Advanced drug delivery systems: Nanotechnology of health design A review.J. Saudi Chem. Soc.2014182859910.1016/j.jscs.2012.12.009
     [Google Scholar]
  133. SubramaniK. PathakS. HosseinkhaniH. Recent trends in diabetes treatment using nanotechnology.Dig. J. Nanomater. Biostruct.7120128595
     [Google Scholar]
  134. NieX. ChenZ. PangL. WangL. JiangH. ChenY. ZhangZ. FuC. RenB. ZhangJ. Oral nano drug delivery systems for the treatment of type 2 diabetes mellitus: An available administration strategy for antidiabetic phytocompounds.Int. J. Nanomedicine202015102151024010.2147/IJN.S28513433364755
     [Google Scholar]
  135. DiSantoR.M. SubramanianV. GuZ. Recent advances in nanotechnology for diabetes treatment.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20157454856410.1002/wnan.132925641955
     [Google Scholar]
  136. PerumalO. MurthyS.N. KaliaY.N. Turning theory into practice: The development of modern transdermal drug delivery systems and future trends.Skin Pharmacol. Physiol.2013264-633134210.1159/00035181523921120
     [Google Scholar]
  137. GuptaD.K. AhadA. AqilM. Al-MohizeaA.M. Al-JenoobiF.I. Chapter 18 - Iontophoretic drug delivery: Concepts, approaches, and applications.Advanced and Modern Approaches for Drug DeliveryAcademic Press202351554610.1016/B978‑0‑323‑91668‑4.00016‑2
     [Google Scholar]
  138. ThirunavukkarasuA. NithyaR. JeyanthiJ. Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: A review.Diabetes Res. Clin. Pract.202219410999610.1016/j.diabres.2022.10999635850300
     [Google Scholar]
  139. YuF. LiY. ChenQ. HeY. WangH. YangL. GuoS. MengZ. CuiJ. XueM. ChenX.D. Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency.Eur. J. Pharm. Biopharm.201610313614810.1016/j.ejpb.2016.03.01927020531
     [Google Scholar]
  140. RiddleM.C. PhilipsonL.H. RichS.S. CarlssonA. FranksP.W. GreeleyS.A.W. NolanJ.J. PearsonE.R. ZeitlerP.S. HattersleyA.T. Monogenic Diabetes: From genetic insights to population-based precision in care. Reflections from a Diabetes Care editors' expert forumDiabetes Care202043123117312810.2337/dci20‑006533560999
     [Google Scholar]
  141. RubanyiG.M. The future of human gene therapy.Mol. Aspects Med.200122311314210.1016/S0098‑2997(01)00004‑811470139
     [Google Scholar]
  142. WirthT. ParkerN. Ylä-HerttualaS. History of gene therapy.Gene2013525216216910.1016/j.gene.2013.03.13723618815
     [Google Scholar]
  143. YongZ. Application of Gene therapy in the perspective of the therapy of type 2 diabetes mellitus.J. Biomed. Biosens.2126312022
     [Google Scholar]
  144. MemonB. AbdelalimE.M. Stem cell therapy for diabetes: Beta cells versus pancreatic progenitors.Cells20209228310.3390/cells902028331979403
     [Google Scholar]
  145. de KlerkE. HebrokM. Stem cell-based clinical trials for diabetes mellitus.Front. Endocrinol. (Lausanne)20211263146310.3389/fendo.2021.63146333716982
     [Google Scholar]
  146. ChenS. DuK. ZouC. Current progress in stem cell therapy for type 1 diabetes mellitus.Stem Cell Res. Ther.202011127510.1186/s13287‑020‑01793‑632641151
     [Google Scholar]
  147. YazhenZ. WenyiC. BingF. HongcuiC. The clinical efficacy and safety of stem cell therapy for diabetes mellitus: A systematic review and meta-analysis.Aging Dis.202011114115310.14336/AD.2019.042132010488
     [Google Scholar]
  148. RiessM.L. ElorbanyR. WeihrauchD. StoweD.F. CamaraA.K.S. PPARγ-independent side effects of thiazolidinediones on mitochondrial redox state in rat isolated hearts.Cells20209125210.3390/cells901025231968546
     [Google Scholar]
  149. GilbertM.P. PratleyR.E. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials.Front. Endocrinol. (Lausanne)20201117810.3389/fendo.2020.0017832308645
     [Google Scholar]
  150. SomtimuangC. OlatunjiO.J. OvatlarnpornC. Evaluation of in vitro α-amylase and α -glucosidase inhibitory potentials of 14 medicinal plants constituted in thai folk antidiabetic formularies.Chem. Biodivers.2018154e180002510.1002/cbdv.20180002529460340
     [Google Scholar]
  151. BenjaminM.A.Z. Mohd MokhtarR.A. IqbalM. AbdullahA. AzizahR. SulistyoriniL. MahfudhN. ZakariaZ.A. Medicinal plants of Southeast Asia with anti-α-glucosidase activity as potential source for type-2 diabetes mellitus treatment.J. Ethnopharmacol.202433011823910.1016/j.jep.2024.11823938657877
     [Google Scholar]
  152. UllahA. MunirS. BadshahS.L. KhanN. GhaniL. PoulsonB.G. EmwasA.H. JaremkoM. Important flavonoids and their role as a therapeutic agent.Molecules20202522524310.3390/molecules2522524333187049
     [Google Scholar]
  153. El-NasharH.A.S. MostafaN.M. El-ShazlyM. EldahshanO.A. The role of plant-derived compounds in managing diabetes mellitus: A review of literature from 2014 to 2019.Curr. Med. Chem.202128234694473010.2174/1875533XMTExDNzIt533231145
     [Google Scholar]
  154. DiasM.C. PintoD.C.G.A. SilvaA.M.S. Plant flavonoids: Chemical characteristics and biological activity.Molecules20212617537710.3390/molecules2617537734500810
     [Google Scholar]
  155. KawabataK. MukaiR. IshisakaA. Quercetin and related polyphenols: New insights and implications for their bioactivity and bioavailability.Food Funct.2015651399141710.1039/C4FO01178C25761771
     [Google Scholar]
  156. AgraharamG. GirigoswamiA. GirigoswamiK. Myricetin: A multifunctional flavonol in biomedicine.Curr. Pharmacol. Rep.202281486110.1007/s40495‑021‑00269‑235036292
     [Google Scholar]
  157. RamešováŠ. SokolováR. DeganoI. BulíčkováJ. ŽabkaJ. GálM. On the stability of the bioactive flavonoids quercetin and luteolin under oxygen-free conditions.Anal. Bioanal. Chem.2012402297598210.1007/s00216‑011‑5504‑322057718
     [Google Scholar]
  158. ChenP. ChenF. GuoZ. LeiJ. ZhouB. Recent advancement in bioeffect, metabolism, stability, and delivery systems of apigenin, a natural flavonoid compound: challenges and perspectives.Front. Nutr.202310122122710.3389/fnut.2023.122122737565039
     [Google Scholar]
  159. CaiJ. WenH. ZhouH. ZhangD. LanD. LiuS. LiC. DaiX. SongT. WangX. HeY. HeZ. TanJ. ZhangJ. Naringenin: A flavanone with anti-inflammatory and anti-infective properties.Biomed. Pharmacother.202316411499010.1016/j.biopha.2023.11499037315435
     [Google Scholar]
  160. ZhaoJ. YangJ. XieY. Improvement strategies for the oral bioavailability of poorly water-soluble flavonoids: An overview.Int. J. Pharm.201957011864210.1016/j.ijpharm.2019.11864231446024
     [Google Scholar]
  161. LigaS. PaulC. PéterF. Flavonoids: Overview of biosynthesis, biological activity, and current extraction techniques.Plants20231214273210.3390/plants1214273237514347
     [Google Scholar]
  162. LotfiM.S. KalaliniaF. Flavonoids in combination with stem cells for the treatment of neurological disorders.Neurochem. Res.202348113270328210.1007/s11064‑023‑03986‑w37462837
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998335480241022084655
Loading
A Mechanism-based Perspective on the Use of Flavonoids in the Treatment of Diabetes and its Complications
Curr. Diabetes Rev. 22, E15733998335480 (2026); https://doi.org/10.2174/0115733998335480241022084655
/content/journals/cdr/10.2174/0115733998335480241022084655
/content/journals/cdr/10.2174/0115733998335480241022084655
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): flavanones; flavanonols; Flavones; flavonols; gestational diabetes; type 1 diabetes; type 2 diabetes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test